查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1870031

基因载体市场规模、份额和趋势分析报告：按类型、递送方式、治疗领域、最终用途、地区和细分市场预测（2025-2033 年）

Gene Vector Market Size, Share & Trends Analysis Report By Type (Viral, Non-Viral), By Delivery Method, By Therapeutic Area, By End Use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

基因载体市场摘要

2024年全球基因载体市场规模估计为78.8亿美元，预计2033年将达到426.1亿美元。

预计2025年至2033年间，该市场将以20.92%的复合年增长率成长。主要成长要素包括遗传疾病盛行率的上升、基因治疗技术的进步以及为开发创新基因递送系统而进行的研发活动的激增。随着对标靶治疗和个人化医疗需求的不断增长，预计该市场将在几个关键地区实现显着增长。

病毒载体和非病毒载体技术的进展

病毒和非病毒载体技术的进步推动了全球基因载体产业的显着成长。腺结合病毒（AAV）、慢病毒和逆转录病毒等病毒载体的持续创新，显着提高了安全性、转导效率和组织特异性靶向性。例如，新一代AAV具有更高的递送效率和更低的免疫抗原性，使其成为治疗遗传性疾病和慢性疾病的理想选择。

非病毒载体技术的进步进一步推动了市场发展。脂质奈米颗粒（LNP）、聚合物载体和电穿孔等物理递送方法因其可扩展性、安全性更高以及能够携带更大基因载荷等优势，正日益成为病毒载体系统的替代方案。尤其是在新冠疫情期间，脂质奈米颗粒作为mRNA疫苗的载体，引起了全球的广泛关注，进一步展现了其在癌症治疗、罕见遗传疾病和感染疾病方面的潜力。提高非病毒载体的递送效率、降低细胞毒性和提高标靶精准度的研究与开发，仍是大规模商业化生产的重要方向。

对个人化医疗的需求日益增长

个人化医疗的日益普及是基因载体市场的主要成长要素。千篇一律的治疗方法往往无法解决复杂罕见疾病的根本病因，因此，基于患者基因谱的个人化治疗方法的需求日益增长。基因载体在开发这些个人化疗法中发挥着至关重要的作用，它们能够将治疗基因直接递送到目标细胞，从而从分子层面而非仅仅缓解症状。随着基因测序和生物标记发现技术的快速发展，医疗服务提供者越来越能够根据患者的基因组成设计专属治疗方法，这也使得病毒载体和非病毒载体在这一转型过程中扮演越来越重要的角色。

全球精准医疗倡议投入的不断增加进一步推动了这一趋势。各国政府、研究机构和製药公司正致力于开发个人化治疗模式，以改善患者疗效、减少副作用并提高医疗成本效益。基因和细胞疗法（通常基于载体）处于这一领域的前沿，越来越多的治疗方法核准用于治疗癌症、罕见遗传疾病和遗传性疾病。

目录

第一章调查方法和范围

第二章执行摘要

第三章 市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 附随市场展望
  • 市场趋势与展望
  • 市场动态
    • 市场驱动因素的影响分析
    • 市场限制因素的影响分析
  • 商业环境分析
    • PESTLE分析
    • 波特五力分析

第四章 基因载体市场：类型业务分析

  • 类型细分仪表板
  • 全球基因载体市场类型及波动分析
  • 全球基因载体市场规模及趋势分析（按类型划分）（2021-2033年）
  • 病毒载体
  • 非病毒载体

5. 基因载体市场：递送方式的业务分析

  • 配送方式细分仪表板
  • 全球基因载体市场递送方式及变异分析
  • 全球基因载体市场规模及趋势分析（依递送方式划分，2021-2033 年）
  • 体内基因递送
  • 体外基因递送
  • 其他的

6. 基因载体市场：治疗领域业务分析

  • 治疗领域细分仪表板
  • 全球基因载体市场治疗领域变迁分析
  • 全球基因载体市场规模及趋势分析（依治疗领域划分，2021-2033 年）
  • 肿瘤学
  • 遗传性疾病
  • 感染疾病
  • 心血管疾病
  • 神经系统疾病
  • 眼科疾病
  • 其他的

7. 基因载体市场：终端用户业务分析

  • 最终用户细分仪表板
  • 全球基因载体市场最终用途及变异分析
  • 全球基因载体市场规模及趋势分析（依最终用途划分，2021-2033 年）
  • 製药和生物技术公司
  • 学术研究机构
  • 合约研究组织 (CRO) 和合约生产组织 (CMO)

8. 基因载体市场：区域估算和趋势分析（按类型、递送方法、治疗领域和最终用途划分）

  • 区域仪錶板
  • 市场规模、预测与趋势分析，2021-2033年
  • 北美洲
    • 2021-2033年北美基因载体市场
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 欧洲基因载体市场，2021-2033年
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 亚太地区基因载体市场，2021-2033年
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 泰国
    • 韩国
  • 拉丁美洲
    • 2021-2033年拉丁美洲基因载具市场
    • 巴西
    • 阿根廷
  • 中东和非洲
    • MEA 基因载体市场，2021-2033
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第九章 竞争情势

  • 公司分类
  • 策略规划
  • 企业市场分析，2024年
  • 公司简介
    • Charles River Laboratories
    • VGXI, Inc.
    • Danaher（Aldevron）
    • Kaneka Corp.
    • Eurofins Genomics
    • Cell and Gene Therapy Catapult
    • Catalent, Inc.
    • Lonza
    • Luminous BioSciences, LLC
    • Akron Biotech
Product Code: GVR-4-68040-757-2

Gene Vector Market Summary

The global gene vector market size was estimated at USD 7.88 billion in 2024 and is projected to reach USD 42.61 billion by 2033, growing at a CAGR of 20.92% from 2025 to 2033. The main growth drivers are the increasing prevalence of genetic disorders, advancements in gene therapy, and a boom in research and development efforts to create innovative gene delivery systems. The market is expected to grow significantly in several important global regions as the need for targeted therapies and personalized medicine keeps growing.

Advancements in Viral and Non-viral Vectors

The global gene vector industry is seeing significant growth due to advancements in viral and non-viral vector technology. Adeno-associated viruses (AAV), lentiviruses, and retroviruses are viral vectors whose safety profiles, transduction efficiency, and tissue-specific targeting have all been greatly enhanced by ongoing innovation. For example, next-generation AAVs are being developed with improved delivery efficiency and decreased immunogenicity, making them ideal for treating inherited and chronic diseases.

The market momentum is being strengthened by the advancements associated with non-viral vectors. Lipid nanoparticles (LNPs), carriers from polymers, and some form of physical delivery, such as electroporation, are increasingly used as alternatives to viral systems because they can be scaled up, have fewer safety concerns, and carry larger genetic payloads. LNPs, specifically, were brought to the forefront of global attention with the COVID-19 pandemic because mRNA vaccines utilized lipid nanoparticles as carriers, further demonstrating their therapeutic potential in the treatment of oncology, rare genetic diseases, and infectious diseases. The dedicated research and development to improve delivery efficiency, reduce cytotoxicity, and improve targeting accuracy of non-viral vectors are still attractive to large-scale commercial manufacturing.

Growing Demand for Personalized Medicine

The rising trend toward personalized medicine is a major growth driver for the gene vector market. Generic, one-size-fits-all treatments often fail to address the underlying cause of complex and rare diseases. This creates a demand for therapy designed for individual patients based on their genetic profile. Gene vectors will be integral to developing these personalized treatments that deliver therapeutic genes directly into targeted cells to help treat the molecular basis of disease, rather than simply addressing symptoms. As advancements in genomic sequencing and biomarker discovery accelerate, healthcare providers are better equipped to design therapies specific to a patient's genetic makeup, which, in turn, is increasing reliance on viral and non-viral vectors as essential tools in this transformation.

Growing investments in precision medicine initiatives across the globe further underscore this trend. Governments, research institutes, and pharmaceutical companies are focusing on personalized treatment models. They aim to improve patient outcomes, reduce side effects, and make healthcare more cost-effective. Gene and cell therapies, many of which are vector-based, are at the forefront of this movement, with increasing approvals of treatments for cancers, rare genetic disorders, and inherited conditions.

Global Gene Vector Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global gene vector market on the basis of type, delivery method, therapeutic area, end use, and region:

  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Viral Vectors
    • Adenoviral Vectors
    • Adeno-Associated Viral (AAV) Vectors
    • Lentiviral Vectors
    • Retroviral Vectors
    • Herpes Simplex Virus (HSV) Vectors
    • Others
  • Non-Viral Vectors
    • Plasmid DNA
    • Lipid Nanoparticles
    • Polymer-based Vectors
    • Others
  • Delivery Method Outlook (Revenue, USD Million, 2021 - 2033)
  • In-vivo Gene Delivery
  • Ex-vivo Gene Delivery
  • Others
  • Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)
  • Oncology
  • Genetic Diseases
  • Infectious Diseases
  • Cardiovascular Diseases
  • Neurological Diseases
  • Ophthalmological Diseases
  • Others
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutes
  • CROs & CMOs
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
    • 1.2.1. Type
    • 1.2.2. Delivery Method
    • 1.2.3. Therapeutic Area
    • 1.2.4. End use
  • 1.3. Information analysis
  • 1.4. Market formulation & data visualization
  • 1.5. Data validation & publishing
  • 1.6. Information Procurement
    • 1.6.1. Primary Research
  • 1.7. Information or Data Analysis
  • 1.8. Market Formulation & Validation
  • 1.9. Market Details
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. Market Trends and Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Driver Impact Analysis
      • 3.3.1.1. Advancements in viral and non-viral vectors
      • 3.3.1.2. Growing demand for personalized medicine
    • 3.3.2. Market Restraint Impact Analysis
      • 3.3.2.1. Regulatory and compliance challenges
  • 3.4. Business Environment Analysis
    • 3.4.1. PESTLE Analysis
    • 3.4.2. PORTER'S Five Forces Analysis

Chapter 4. Gene Vector Market: Type Business Analysis

  • 4.1. Type Segment Dashboard
  • 4.2. Global Gene Vector Market Type, Movement Analysis
  • 4.3. Global Gene Vector Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
  • 4.4. Viral Vectors
    • 4.4.1. Global viral vectors market estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.4.2. Adenoviral Vectors
      • 4.4.2.1. Global adenoviral vectors market estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.4.3. Adeno-Associated Viral (AAV) Vectors
      • 4.4.3.1. Global adeno-associated viral (AAV) Vectors market estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.4.4. Lentiviral Vectors
      • 4.4.4.1. Global lentiviral vectors market estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.4.5. Retroviral Vectors
      • 4.4.5.1. Global retroviral vectors market estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.4.6. Herpes Simplex Virus (HSV) Vectors
      • 4.4.6.1. Global herpes simplex virus (HSV) Vectors market estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.4.7. Others
      • 4.4.7.1. Global other viral vectors market estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.5. Non-Viral Vectors
    • 4.5.1. Global non-viral vectors market estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.5.2. Plasmid DNA
      • 4.5.2.1. Global plasmid DNA market estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.5.3. Lipid Nanoparticles
      • 4.5.3.1. Global lipid nanoparticles market estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.5.4. Polymer-based Vectors
      • 4.5.4.1. Global polymer-based vectors market estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.5.5. Others
      • 4.5.5.1. Global other non-viral vectors market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 5. Gene Vector Market: Delivery Method Business Analysis

  • 5.1. Delivery Method Segment Dashboard
  • 5.2. Global Gene Vector Market Delivery Method, Movement Analysis
  • 5.3. Global Gene Vector Market Size & Trend Analysis, by Delivery Method, 2021 to 2033 (USD Million)
  • 5.4. In-vivo Gene Delivery
    • 5.4.1. Global in-vivo gene delivery market estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.5. Ex-vivo Gene Delivery
    • 5.5.1. Global ex-vivo gene delivery market estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.6. Others
    • 5.6.1. Global others market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 6. Gene Vector Market: Therapeutic Area Business Analysis

  • 6.1. Therapeutic Area Segment Dashboard
  • 6.2. Global Gene Vector Market Therapeutic Area, Movement Analysis
  • 6.3. Global Gene Vector Market Size & Trend Analysis, by Therapeutic Area, 2021 to 2033 (USD Million)
  • 6.4. Oncology
    • 6.4.1. Global oncology market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.5. Genetic Diseases
    • 6.5.1. Global genetic disease market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.6. Infectious Diseases
    • 6.6.1. Global infectious disease market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.7. Cardiovascular Diseases
    • 6.7.1. Global cardiovascular disease market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.8. Neurological Diseases
    • 6.8.1. Global neurological disease market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.9. Ophthalmological Diseases
    • 6.9.1. Global ophthalmological disease market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.10. Others
    • 6.10.1. Global others market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 7. Gene Vector Market: End Use Business Analysis

  • 7.1. End Use Segment Dashboard
  • 7.2. Global Gene Vector Market End use, Movement Analysis
  • 7.3. Global Gene Vector Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
  • 7.4. Pharmaceutical & Biotechnology Companies
    • 7.4.1. Global pharmaceutical & biotechnology companies market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5. Academic & Research Institutes
    • 7.5.1. Global academic & research institutes market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.6. CROs & CMOs
    • 7.6.1. Global CROs & CMOs market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 8. Gene Vector Market: Regional Estimates and Trend Analysis, by Type, Delivery Method, Therapeutic Area, & End Use

  • 8.1. Regional Dashboard
  • 8.2. Market Size & Forecasts and Trend Analysis, 2021 to 2033
  • 8.3. North America
    • 8.3.1. North America gene vector market, 2021 - 2033 (USD Million)
    • 8.3.2. U.S.
      • 8.3.2.1. Key Country Dynamics
      • 8.3.2.2. Competitive Scenario
      • 8.3.2.3. Regulatory Framework
      • 8.3.2.4. U.S. gene vector market, 2021 - 2033 (USD Million)
    • 8.3.3. Canada
      • 8.3.3.1. Key Country Dynamics
      • 8.3.3.2. Competitive Scenario
      • 8.3.3.3. Regulatory Framework
      • 8.3.3.4. Canada gene vector market, 2021 - 2033 (USD Million)
    • 8.3.4. Mexico
      • 8.3.4.1. Key Country Dynamics
      • 8.3.4.2. Competitive Scenario
      • 8.3.4.3. Regulatory Framework
      • 8.3.4.4. Mexico gene vector market, 2021 - 2033 (USD Million)
  • 8.4. Europe
    • 8.4.1. Europe gene vector market, 2021 - 2033 (USD Million)
    • 8.4.2. UK
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Competitive Scenario
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. UK gene vector market, 2021 - 2033 (USD Million)
    • 8.4.3. Germany
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Competitive Scenario
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Germany gene vector market, 2021 - 2033 (USD Million)
    • 8.4.4. France
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Competitive Scenario
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. France gene vector market, 2021 - 2033 (USD Million)
    • 8.4.5. Italy
      • 8.4.5.1. Key Country Dynamics
      • 8.4.5.2. Competitive Scenario
      • 8.4.5.3. Regulatory Framework
      • 8.4.5.4. Italy gene vector market, 2021 - 2033 (USD Million)
    • 8.4.6. Spain
      • 8.4.6.1. Key Country Dynamics
      • 8.4.6.2. Competitive Scenario
      • 8.4.6.3. Regulatory Framework
      • 8.4.6.4. Spain gene vector market, 2021 - 2033 (USD Million)
    • 8.4.7. Denmark
      • 8.4.7.1. Key Country Dynamics
      • 8.4.7.2. Competitive Scenario
      • 8.4.7.3. Regulatory Framework
      • 8.4.7.4. Denmark gene vector market, 2021 - 2033 (USD Million)
    • 8.4.8. Sweden
      • 8.4.8.1. Key Country Dynamics
      • 8.4.8.2. Competitive Scenario
      • 8.4.8.3. Regulatory Framework
      • 8.4.8.4. Sweden gene vector market, 2021 - 2033 (USD Million)
    • 8.4.9. Norway
      • 8.4.9.1. Key Country Dynamics
      • 8.4.9.2. Competitive Scenario
      • 8.4.9.3. Regulatory Framework
      • 8.4.9.4. Norway gene vector market, 2021 - 2033 (USD Million)
  • 8.5. Asia Pacific
    • 8.5.1. Asia Pacific gene vector market, 2021 - 2033 (USD Million)
    • 8.5.2. Japan
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Competitive Scenario
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Japan gene vector market, 2021 - 2033 (USD Million)
    • 8.5.3. China
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Competitive Scenario
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. China gene vector market, 2021 - 2033 (USD Million)
    • 8.5.4. India
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Competitive Scenario
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. India gene vector market, 2021 - 2033 (USD Million)
    • 8.5.5. Australia
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Competitive Scenario
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. Australia gene vector market, 2021 - 2033 (USD Million)
    • 8.5.6. Thailand
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Competitive Scenario
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Thailand gene vector market, 2021 - 2033 (USD Million)
    • 8.5.7. South Korea
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Competitive Scenario
      • 8.5.7.3. Regulatory Framework
      • 8.5.7.4. South Korea gene vector market, 2021 - 2033 (USD Million)
  • 8.6. Latin America
    • 8.6.1. Latin America gene vector market, 2021 - 2033 (USD Million)
    • 8.6.2. Brazil
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Competitive Scenario
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Brazil gene vector market, 2021 - 2033 (USD Million)
    • 8.6.3. Argentina
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Competitive Scenario
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Argentina gene vector market, 2021 - 2033 (USD Million)
  • 8.7. MEA
    • 8.7.1. MEA gene vector market, 2021 - 2033 (USD Million)
    • 8.7.2. South Africa
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Competitive Scenario
      • 8.7.2.3. Regulatory Framework
      • 8.7.2.4. South Africa gene vector market, 2021 - 2033 (USD Million)
    • 8.7.3. Saudi Arabia
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Competitive Scenario
      • 8.7.3.3. Regulatory Framework
      • 8.7.3.4. Saudi Arabia gene vector market, 2021 - 2033 (USD Million)
    • 8.7.4. UAE
      • 8.7.4.1. Key Country Dynamics
      • 8.7.4.2. Competitive Scenario
      • 8.7.4.3. Regulatory Framework
      • 8.7.4.4. UAE gene vector market, 2021 - 2033 (USD Million)
    • 8.7.5. Kuwait
      • 8.7.5.1. Key Country Dynamics
      • 8.7.5.2. Competitive Scenario
      • 8.7.5.3. Regulatory Framework
      • 8.7.5.4. Kuwait gene vector market, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization
  • 9.2. Strategy Mapping
  • 9.3. Company Market Position Analysis, 2024
  • 9.4. Company Profiles/Listing
    • 9.4.1. Charles River Laboratories
      • 9.4.1.1. Overview
      • 9.4.1.2. Financial Performance
      • 9.4.1.3. Product Benchmarking
      • 9.4.1.4. Strategic Initiatives
    • 9.4.2. VGXI, Inc.
      • 9.4.2.1. Overview
      • 9.4.2.2. Financial Performance
      • 9.4.2.3. Product Benchmarking
      • 9.4.2.4. Strategic Initiatives
    • 9.4.3. Danaher (Aldevron)
      • 9.4.3.1. Overview
      • 9.4.3.2. Financial Performance
      • 9.4.3.3. Product Benchmarking
      • 9.4.3.4. Strategic Initiatives
    • 9.4.4. Kaneka Corp.
      • 9.4.4.1. Overview
      • 9.4.4.2. Financial Performance
      • 9.4.4.3. Product Benchmarking
      • 9.4.4.4. Strategic Initiatives
    • 9.4.5. Eurofins Genomics
      • 9.4.5.1. Overview
      • 9.4.5.2. Financial Performance
      • 9.4.5.3. Product Benchmarking
      • 9.4.5.4. Strategic Initiatives
    • 9.4.6. Cell and Gene Therapy Catapult
      • 9.4.6.1. Overview
      • 9.4.6.2. Financial Performance
      • 9.4.6.3. Product Benchmarking
      • 9.4.6.4. Strategic Initiatives
    • 9.4.7. Catalent, Inc.
      • 9.4.7.1. Overview
      • 9.4.7.2. Product Benchmarking
      • 9.4.7.3. Strategic Initiatives
    • 9.4.8. Lonza
      • 9.4.8.1. Overview
      • 9.4.8.2. Financial Performance
      • 9.4.8.3. Product Benchmarking
      • 9.4.8.4. Strategic Initiatives
    • 9.4.9. Luminous BioSciences, LLC
      • 9.4.9.1. Overview
      • 9.4.9.2. Financial Performance
      • 9.4.9.3. Product Benchmarking
      • 9.4.9.4. Strategic Initiatives
    • 9.4.10. Akron Biotech
      • 9.4.10.1. Overview
      • 9.4.10.2. Financial Performance
      • 9.4.10.3. Product Benchmarking
      • 9.4.10.4. Strategic Initiatives

List of Tables

  • Table 1. List of Secondary Sources
  • Table 2. List of Abbreviations
  • Table 3. Global Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 4. Global Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 5. Global Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 6. Global Gene Vector Market, by End Use, 2021 - 2033 (USD Million)
  • Table 7. Global Gene Vector Market, by Region, 2021 - 2033 (USD Million)
  • Table 8. North America Gene Vector Market, by Country, 2021 - 2033 (USD Million)
  • Table 9. North America Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 10. North America Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 11. North America Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 12. North America Gene Vector Market, by End Use, 2021 - 2033 (USD Million)
  • Table 13. U.S. Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 14. U.S. Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 15. U.S. Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 16. U.S. Gene Vector Market, by End Use, 2021 - 2033 (USD Million)
  • Table 17. Canada Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 18. Canada Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 19. Canada Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 20. Canada Gene Vector Market, by End Use, 2021 - 2033 (USD Million)
  • Table 21. Mexico Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 22. Mexico Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 23. Mexico Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 24. Mexico Gene Vector Market, by End Use, 2021 - 2033 (USD Million)
  • Table 25. Europe Gene Vector Market, by Country, 2021 - 2033 (USD Million)
  • Table 26. Europe Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 27. Europe Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 28. Europe Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 29. Europe Gene Vector Market, by End Use, 2021 - 2033 (USD Million)
  • Table 30. Germany Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 31. Germany Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 32. Germany Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 33. Germany Gene Vector Market, by End Use, 2021 - 2033 (USD Million)
  • Table 34. UK Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 35. UK Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 36. UK Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 37. UK Gene Vector Market, by End Use, 2021 - 2033 (USD Million)
  • Table 38. France Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 39. France Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 40. France Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 41. France Gene Vector Market, by End Use, 2021 - 2033 (USD Million)
  • Table 42. Italy Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 43. Italy Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 44. Italy Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 45. Italy Gene Vector Market, by End Use, 2021 - 2033 (USD Million)
  • Table 46. Spain Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 47. Spain Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 48. Spain Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 49. Spain Gene Vector Market, by End Use, 2021 - 2033 (USD Million)
  • Table 50. Denmark Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 51. Denmark Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 52. Denmark Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 53. Denmark Gene Vector Market, by End Use, 2021 - 2033 (USD Million)
  • Table 54. Norway Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 55. Norway Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 56. Norway Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 57. Norway Gene Vector Market, by End Use, 2021 - 2033 (USD Million)
  • Table 58. Sweden Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 59. Sweden Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 60. Sweden Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 61. Sweden Gene Vector Market, by End Use, 2021 - 2033 (USD Million)
  • Table 62. Asia Pacific Gene Vector Market, by Country, 2021 - 2033 (USD Million)
  • Table 63. Asia Pacific Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 64. Asia Pacific Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 65. Asia Pacific Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 66. Asia Pacific Gene Vector Market, by End Use, 2021 - 2033 (USD Million)
  • Table 67. China Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 68. China Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 69. China Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 70. China Gene Vector Market, by End Use, 2021 - 2033 (USD Million)
  • Table 71. Japan Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 72. Japan Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 73. Japan Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 74. Japan Gene Vector Market, by End Use, 2021 - 2033 (USD Million)
  • Table 75. India Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 76. India Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 77. India Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 78. India Gene Vector Market, by End Use, 2021 - 2033 (USD Million)
  • Table 79. South Korea Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 80. South Korea Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 81. South Korea Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 82. South Korea Gene Vector Market, by End Use, 2021 - 2033 (USD Million)
  • Table 83. Australia Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 84. Australia Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 85. Australia Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 86. Australia Gene Vector Market, by End Use, 2021 - 2033 (USD Million)
  • Table 87. Thailand Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 88. Thailand Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 89. Thailand Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 90. Thailand Gene Vector Market, by End Use, 2021 - 2033 (USD Million)
  • Table 91. Latin America Gene Vector Market, by Country, 2021 - 2033 (USD Million)
  • Table 92. Latin America Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 93. Latin America Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 94. Latin America Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 95. Latin America Gene Vector Market, by End Use, 2021 - 2033 (USD Million)
  • Table 96. Brazil Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 97. Brazil Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 98. Brazil Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 99. Brazil Gene Vector Market, by End Use, 2021 - 2033 (USD Million)
  • Table 100. Argentina Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 101. Argentina Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 102. Argentina Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 103. Argentina Gene Vector Market, by End Use, 2021 - 2033 (USD Million)
  • Table 104. Middle East and Africa Gene Vector Market, by Country, 2021 - 2033 (USD Million)
  • Table 105. Middle East and Africa Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 106. Middle East and Africa Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 107. Middle East and Africa Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 108. Middle East and Africa Gene Vector Market, by End Use, 2021 - 2033 (USD Million)
  • Table 109. South Africa Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 110. South Africa Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 111. South Africa Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 112. South Africa Gene Vector Market, by End use, 2021 - 2033 (USD Million)
  • Table 113. Saudi Arabia Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 114. Saudi Arabia Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 115. Saudi Arabia Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 116. Saudi Arabia Gene Vector Market, by End Use, 2021 - 2033 (USD Million)
  • Table 117. UAE Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 118. UAE Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 119. UAE Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 120. UAE Gene Vector Market, by End Use, 2021 - 2033 (USD Million)
  • Table 121. Kuwait Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 122. Kuwait Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 123. Kuwait Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 124. Kuwait Gene Vector Market, by End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Gene vector market segmentation
  • Fig. 2 Data analysis models
  • Fig. 3 Market formulation and validation
  • Fig. 4 Data validation & publishing
  • Fig. 5 Market research process
  • Fig. 6 Information procurement
  • Fig. 7 Primary research
  • Fig. 8 Value-chain-based sizing & forecasting
  • Fig. 9 QFD modelling for market share assessment
  • Fig. 10 Market formulation & validation
  • Fig. 11 Commodity flow analysis
  • Fig. 12 Market outlook
  • Fig. 13 Segment snapshot-1
  • Fig. 14 Competitive landscape snapshot
  • Fig. 15 Market trends & outlook
  • Fig. 16 PESTEL analysis
  • Fig. 17 Porter's five forces analysis
  • Fig. 18 Gene vector market: Type outlook key takeaways
  • Fig. 19 Gene vector market: Type movement analysis
  • Fig. 20 Viral vectors market, 2021 - 2033 (USD Million)
  • Fig. 21 Non-viral vectors market, 2021 - 2033 (USD Million)
  • Fig. 22 Gene vector market: Delivery Method outlook key takeaways
  • Fig. 23 Gene vector market: Delivery Method movement analysis
  • Fig. 24 In-vivo gene delivery, 2021 - 2033 (USD Million)
  • Fig. 25 Ex-vivo gene delivery, 2021 - 2033 (USD Million)
  • Fig. 26 Others, 2021 - 2033 (USD Million)
  • Fig. 27 Gene vector market: Therapeutic Area outlook key takeaways
  • Fig. 28 Gene vector market: Therapeutic Area movement analysis
  • Fig. 29 Oncology, 2021 - 2033 (USD Million)
  • Fig. 30 Genetic Diseases, 2021 - 2033 (USD Million)
  • Fig. 31 Infectious Diseases, 2021 - 2033 (USD Million)
  • Fig. 32 Cardiovascular Diseases, 2021 - 2033 (USD Million)
  • Fig. 33 Neurological Diseases, 2021 - 2033 (USD Million)
  • Fig. 34 Ophthalmological Diseases, 2021 - 2033 (USD Million)
  • Fig. 35 Others, 2021 - 2033 (USD Million)
  • Fig. 36 Gene vector market: End use outlook key takeaways
  • Fig. 37 Gene vector market: End use movement analysis
  • Fig. 38 Pharmaceutical & biotechnology companies market, 2021 - 2033 (USD Million)
  • Fig. 39 Academic & research institutions market, 2021 - 2033 (USD Million)
  • Fig. 40 CROs & CMOs market, 2021 - 2033 (USD Million)
  • Fig. 41 Regional marketplace outlook, 2024 & 2033 (USD Million)
  • Fig. 42 Regional marketplace: Key takeaways
  • Fig. 43 North America gene vector market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 44 Key country dynamics
  • Fig. 45 U.S. gene vector market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 46 Key country dynamics
  • Fig. 47 Canada gene vector market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 48 Key country dynamics
  • Fig. 49 Mexico gene vector market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 50 Europe gene vector market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 51 Key country dynamics
  • Fig. 52 Germany gene vector market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 53 Key country dynamics
  • Fig. 54 UK gene vector market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 France gene vector market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 Italy gene vector market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 59 Key country dynamics
  • Fig. 60 Spain gene vector market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 61 Key country dynamics
  • Fig. 62 Denmark gene vector market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 63 Key country dynamics
  • Fig. 64 Sweden gene vector market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 65 Key country dynamics
  • Fig. 66 Norway gene vector market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 67 Asia Pacific gene vector market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 68 Key country dynamics
  • Fig. 69 Japan gene vector market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 China gene vector market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 India gene vector market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 South Korea gene vector market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 76 Key country dynamics
  • Fig. 77 Australia gene vector market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 78 Key country dynamics
  • Fig. 79 Thailand gene vector market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 80 Latin America gene vector market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 81 Key country dynamics
  • Fig. 82 Brazil gene vector market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 83 Key country dynamics
  • Fig. 84 Argentina gene vector market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 85 MEA gene vector market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 86 Key country dynamics
  • Fig. 87 South Africa gene vector market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 88 Key country dynamics
  • Fig. 89 Saudi Arabia gene vector market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 90 Key country dynamics
  • Fig. 91 UAE gene vector market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 92 Key country dynamics
  • Fig. 93 Kuwait gene vector market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 94 Market position analysis
  • Fig. 95 Market participant categorization
  • Fig. 96 Strategic framework